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Rapidly renewing tissues such as the intestinal epithelium critically depend
on the activity of small-sized stem cell populations that continuously gener-
ate new progeny to replace lost and damaged cells. The complex and tightly
regulated process of intestinal homeostasis is governed by a variety of sig-
nalling pathways that balance cell proliferation and differentiation.
Accumulating evidence suggests that stem cell control and daughter cell
fate determination is largely dictated by the microenvironment. Here, we
review recent developments in the understanding of intestinal stem cell
dynamics, focusing on the roles, mechanisms and interconnectivity of
prime signalling pathways that regulate stem cell behaviour in intestinal
homeostasis. Furthermore, we discuss how mutational activation of these
signalling pathways endows colorectal cancer cells with niche-independent
growth advantages during carcinogenesis.1. Adult stem cells are critical for tissue homeostasis
Adult tissue homeostasis strictly depends on the balanced generation of new cells
that replenish cells that are lost through natural attrition or tissue injury. This pro-
cess of tissue regeneration is fuelled by small populations of stem cells that are
defined by their unique ability to renew themselves persistently (self-renewal)
while also giving rise to the specialized cell types of the pertinent tissue (multi-
potency) [1–3]. These adult stem cells are generally referred to by their tissue of
origin (e.g. haematopoietic, neuronal or intestinal stem cells (ISCs)). Depending
on local needs, stem cells may switch their mode of cell division from symmetric
to asymmetric. Symmetric division gives rise to two identical daughter cells, both
endowed with stem cell properties. Asymmetric division produces only one stem
cell and a progenitor cell via signals from the microenvironment and unequal
segregation of proteins or RNA, which direct distinct gene expression profiles
that control the fate of the newly generated cell [4,5].
Stem cell activity is for a large part dictated externally by the microenviron-
ment (the stem cell niche) to precisely control stem cell output and meet the
homeostatic or regenerative demands of the tissue. Extracellular cues, provided
by neighbouring niche cells, locally interact with stem cells to regulate their fate
by activating specific signalling pathways. Here, we review current knowledge
onhow stemcells receive and interpret extracellular signals from their niche, focus-
ing on the prototypemodel of ISCs,which undergo rapid self-renewal kinetics and
give rise to the multiple specialized lineages of the intestinal epithelium [6].
2. Intestinal architecture
The intestinal mucosa has evolved to absorb water and nutrients while at the

































Figure 1. Architecture of the small intestine and the controlling signalling pathways. Actively cycling Lgr5-positive crypt base columnar (CBC) stem cells reside at the
bottom of the crypt intermingled with Paneth cells. The stem cells give rise to transit amplifying (TA) cells that terminally differentiate towards all epithelial lineages
of the villus. Position 4 (þ4) stem cells are mobilized upon tissue damage. Intestinal homeostasis is governed by an interconnected network of signalling pathways,




2continuous renewal of the gut epithelium allows cells
towards the end of their lifetime to shed off at the tip of the
villus, while newly produced and differentiated cells migrate
up and restock the epithelial barrier. This endless process is
sustained by symmetrically dividing stem cells that reside
at the crypt base (figure 1).
The intestinal epithelial lining represents one of the most
intensively self-replenishing organs; within 5 days the entire
epithelial layer is renewed [7]. The architecture of the intestine
is designed to maximize the surface for nutrient uptake and is
folded into large numbers of villi and crypts in the small intes-
tine. The colon is also folded into crypts but does not display
villi. ISCs reside at the bottom of the crypts and are able to
replenish the whole crypt–villus axis, generating all differen-
tiated cell types required for the physiological function of the
intestine (figure 1). Newly born cells first give rise to the
rapidly proliferating subset of progenitors, also known as
transit amplifying (TA) cells, that occupy the crypts and
expand the population required for epithelial turnover. They
migrate upwards while differentiating into one of the special-
ized epithelial lineages [8]. Among the differentiated cell
types, nutrient absorbing enterocytes make up the majority
of cells lining the villi. Other major lineages are secretory
cell types such as goblet cells that produce mucus to generatea protective barrier and enteroendocrine cells that secrete var-
ious hormones that exert both local and systemic regulatory
effects. Furthermore, specialized Paneth cells escape the
upward flow and migrate downward to constitute the niche
for ISCs at the crypt base [9,10], secreting antimicrobial pep-
tides and essential factors for stem cell maintenance. Finally,
two more rare cell types are produced, comprising secretory
Tuft cells that serve as sensors for luminal contents and
initiate type 2 immune responses to helminth infections
[11–14], and M (microfold) cells that reside in specialized epi-
thelium overlying Peyer’s patches to communicate with the
gut’s immune system [15]. The continuous proliferation of
crypt cells is ultimately balanced by shedding of apoptotic
cells at the tip of the villus into the lumen (figure 1).3. Intestinal stem cells
3.1. Plasticity of intestinal stem cells
At present, several populations of ISCs have been described
based on their markers and localization in the crypt. Among
these are the fast-cycling crypt base columnar (CBC) stem




3G-protein coupled receptor 5 (Lgr5) [1,7,16]. In addition, a
slow dividing, ‘reserve stem cell’ population was ident-
ified, also called position 4/þ4 cells or label-retaining cells
(LRCs) [16–19].
The Lrg5-positive CBC cells that divide every day are con-
sidered the driving force of intestinal tissue renewal. Lineage
tracing experiments in mice showed that all epithelial cell
types originate from the CBC cells that produced clonal rib-
bons of progeny with lifelong perseverance [1]. To date,
Lgr5 has been validated as a bona fide stem cell marker
not only in the intestine but also in the stomach pylorus
[20] and corpus [21], and hair follicle [22]. Expression profil-
ing of sorted intestinal Lgr5-positive cells provided a CBC
stem cell gene expression signature [23,24], which allowed
for further functional analysis of additional stem cell
genes, such as Achaete-scute complex homolog 2 (Ascl2) [8,25,26],
tumour necrosis factor receptor superfamily member 19 (TNFRSF19)
or Troy [27], Olfactomedin 4 (Olfm4) [28] and SPARC related
modulator calcium binding 2 (Smoc2) [23].
The pool of slow cycling reserve stem cells is considered to
comprise quiescent stem cells that are mobilized upon tissue
damage [18,19]. Severalmarkers for these cells were identified,
including polycomb protein B lymphomaMo-MLV insertion region
1 homolog (Bmi1) [29], telomerase reverse transcriptase (Tert) [30],
homeobox-only protein (Hopx) [31] and leucine-rich repeats and
immunoglobulin-like domains 1 (Lrig1) [32,33].
Additionally, several secretory progenitor populations
showed the ability to de-differentiate and revert to stem-like
cells to replenish the crypt upon extensive tissue damage.
This property was ascribed to LRCs [34] as well as to progeni-
tors that express the Notch ligand Delta-like 1 (Dll1) [35], and
to Paneth cells upon irradiation [36]. Furthermore, in addition
to cells of the secretory lineage, a recent study showed that
the abundant enterocyte progenitors of the absorptive lineage
can dedifferentiate and replace lost ISCs upon ablation of
Lgr5-expressing stem cells as well [37].
In conclusion, crypt cells display substantial plasticity,
employing CBC stem cells for regular tissue renewal and
reserve stem cells to act upon tissue damage. Stemness, there-
fore, appears extrinsically imposed on cells, placing niche
signals centre stage for regulating ISC function and intestinal
homeostasis.
3.2. Lgr5-positive crypt base columnar stem cells
In this review, we refer to Lgr5-positive CBCs when discussing
ISCs. Lgr5-positive CBC stem cells divide once a day, generat-
ing new CBC cells that reside at the crypt base as stem cells
[38]. Owing to the limited space in the crypt base, however,
half of the ISCs are randomly pushed out of the niche to
become committed progenitor cells, a process called ‘neutral
competition’ [38,39]. In this model, all ISCs initially carry the
same properties and therefore have a similar chance to persist
as an ISC. Real-time intravital imaging confirmed this mech-
anism in vivo [39]. However, detailed quantitative analysis of
individual clonal ISC lineages showed that ‘central cells’ at
the crypt base have an advantage over ‘border cells’ in the
upper rim of the crypt niche for long-term persistence.
Border cells were more likely to be displaced into the transit-
amplifying compartment, lose their stem cell properties and
differentiate along the crypt–villus axis [39]. The spectrum
of stem cell activity displays heterogeneity, even within the
pool of cells expressing Lgr5. These cells are probably ableto transit between states of variable competence, directed
by niche-derived signals [39].4. Intestinal stem cell niche
What constitutes and determines the niche for ISCs? The stem
cell niche provides a nurturing and guiding environment that
sustains the self-renewing, multipotent stem cell population.
At the same time, the niche provides local cues for the gener-
ation and positioning of differentiated progeny. The ISC
niche is constituted by neighbouring Paneth cells within the
epithelial layer, and by myofibroblasts, fibroblasts, neuronal
and smooth muscle cells within the subepithelial mesench-
yme that tightly line the crypt base basal lamina and the
extracellular matrix [10,40,41] (figure 1). The close association
and direct contact of these niche cells with ISCs facilitates the
supply of essential factors for ISC maintenance and prolifer-
ation. The subepithelial mesenchyme produces various Wnts
and epidermal growth factor (EGF) [42–44]. Furthermore,
these cells provide R-spondins, potent Wnt signalling ago-
nists, and Noggin, gremlin 1/2 and chordin-like 1,
inhibitors of bone morphogenetic protein (BMP), to repress
BMP-mediated differentiation [40,42,45–47]. Recently, sube-
pithelial telocytes were demonstrated to be a vital source of
Wnt ligands, as blockage of Wnt secretion from these rare,
large cells results in impaired epithelial renewal and disrup-
tion of intestinal integrity [48,49]. Similarly, subepithelial
Gli1-positive mesenchymal cells provide a crucial source of
Wnts, as blockage of Wnt secretion from these cells also
results in stem cell loss and subsequent loss of colonic epi-
thelium integrity, which ultimately leads to epithelial death
[50]. In addition, within the epithelium, Paneth cells provide
essential growth signals, including Wnt3, EGF and Notch
ligands, described in detail below [10,42]. Interestingly, abla-
tion of Paneth cells does not result in ISC depletion in vivo,
but in vitro cultured mini-guts (intestinal organoids), however,
lack the mesenchymal component and as such fully depend
on Wnt3 production by Paneth cells for stem cell maintenance
and renewal of the epithelium [10,51]. These combined find-
ings show that both mesenchymal cells, especially telocytes
and Gli1þ cells, and Paneth cells serve as important sources
for growth factors in the control of tissue renewal.
Thus, ISCs and daughter cells are subjected to and directed
by a broad array of signals present in their niche. Polarized
gradients of these mesenchymal- and epithelial-derived
signals exist both in the crypt and also along the crypt–
villus axis (figure 1). The balance between the generation of
new cells and their functional specialization is regulated by
numerous signalling pathways, which control proper ISC
maintenance and intestinal architecture. Among these are
the Wnt/b-catenin, Notch, Hedgehog, BMP, EGF and Eph–
ephrin signalling cascades (figure 2). Below, we review these
pathways and how their interconnected circuitry governs
intestinal homeostasis.
5. Wnt signalling controls maintenance
and size of the intestinal stem cell zone
5.1. Wnt signalling
The conserved Wnt signalling pathway determines crucial



























































Figure 2. Multiple key signalling pathways govern intestinal homeostasis. Representation of the principal signalling cascades of Notch, Hedgehog (Hh), Wnt, bone
morphogenetic protein (BMP), epidermal growth factor (EGF) and Eph–ephrin that together control stem cell behaviour and intestinal homeostasis, see text for
further details. Dll, delta-like ligand; NICD, Notch intracellular domain; g, g-secretase; Hh, Hedgehog; Ptch, Patched; Smo, Smoothend; Gli, glioblastoma; GliR, Gli
repressor; GliA, Gli activator; Lrp6, low-densitiy lipoprotein receptor-related protein 6; FZD, Frizzled; RNF43, RING finger protein 43; Lgr5, leucine-rich-repeat contain-
ing G-protein coupled receptor 5; R-spo, R-spondin; CK, casein kinase; GSK3, glycogen synthase kinase; Dvl, Dishevelled; p, phospho-group; APC, adenomatous
polyposis coli; bcat, b-catenin; TCF, T cell-specific transcription factor; BMP, bone morphogenetic protein; Bmpr I/II, BMP type I or II receptor; EGF, epidermal
growth factor; EGFR, EGF receptor; PI3K, phosphoinositide 3-kinase; Jak, Janus kinase; STAT, signal transducer and activator of transcription; JNK, c-Jun N-terminal





4homeostasis in adult organisms. It has emerged as a pivotal
player in the specification andmaintenance of stem cell compart-
ments in a wide array of tissues and organs. In the intestine,
Wnt signalling is the main driving force of crypt proliferation.
Wnt ligands, produced by both Paneth and surrounding
stromal cells, bind to their cognate receptors Frizzled (FZD)
and low-density lipoprotein receptor-related protein 5/6
(Lrp5/6) at the surface of adjacent stem cells. Subsequent
activation of the canonical Wnt pathway leads to the accumu-
lation and nuclear entry of the transcriptional co-activator
b-catenin to drive the expression of target genes involved in
stem cell maintenance [6,52]. Wnt-induced stabilization of
b-catenin involves the inactivation of a large multi-protein
complex composed of the scaffold proteins Axin and adeno-
matous polyposis coli (APC) as well as the kinases
glycogen synthase kinase 3b (GSK3b) and casein kinase 1
(CK1). In unstimulated cells, this destruction complex cap-
tures b-catenin and earmarks it for proteolysis through
Ser/Thr phosphorylation of its flexible N-terminus [53,54].
Recognition of phospho-b-catenin by the ubiquitin ligase
b-TrCP subsequently mediates its rapid ubiquitin-mediated
proteasomal degradation [55,56].Binding of Wnt to the FZD and Lrp6 receptors at the cell
surface interferes with b-catenin degradation by a number of
molecular rearrangements. After formation of a trimeric
Wnt–FZD–Lrp5/6 complex, the cytoplasmic effector protein
Dishevelled (Dvl) is recruited. Next, the activated receptor
complex captures the destruction complex organiser Axin,
probably through heterodimerization of the Axin and Dvl
DIX domains [57–59]. The Axin-associated kinases GSK3b
and CK1 turn their activity to the cytoplasmic tail of Lrp6,
which, upon phosphorylation, provides a docking site for
further Axin proteins. The redistribution of Axin–kinase
complexes to the plasma membrane is considered a key
step in the inactivation of b-catenin destruction. As a conse-
quence, the pool of intracellular b-catenin increases and
migrates to the nucleus to bind the T-cell factor (TCF)
family of DNA-bound transcription factors and induces tran-
scription of Wnt target genes (figure 2) [60]. Among the
earliest target genes discovered is c-Myc, a well-known
driver of proliferation of undifferentiated cells [61]. The
Wnt target gene list has vastly expanded ever since, revealing
multiple layers of positive and negative feedback regulation




55.2. Wnt signalling in the intestine
The first clues for the crucial role of Wnt in the intestine ori-
ginated from mouse genetic experiments. Neonatal mice
deleted for TCF4, one of the main downstream effectors of
Wnt, completely lack proliferative crypts, illustrating the
requirement of Wnt signalling for establishment and main-
tenance of the stem cell compartment [66]. Maintenance of
adult crypt proliferation remains dependent on Wnt signal-
ling as conditional deletion of TCF4 in adult mice resulted
in the loss of nearly all proliferating crypts, coinciding with
progressive loss of Wnt target gene expression [67]. Further-
more, conditional deletion of b-catenin as well as
overexpression of the diffusible Wnt inhibitor Dickkopf 1
(Dkk1) results in complete ablation of intestinal crypts in
the adult mouse [68–71]. Moreover, transgenic expression
of R-spondin 1 (R-Spo1), a strong Wnt agonist that acts
through the Lgr4/5–Wnt receptor complex (described in
more detail below), results in a massive hyperproliferation
of intestinal crypts [72]. On the other hand, simultaneous del-
etion of both Lgr4 and Lgr5, the receptors for R-Spo, leads to
the disappearance of crypts [73].
The fact that Wnt signalling plays a vital role in ISC main-
tenance is further illustrated by the nuclear b-catenin levels
that are highest at the crypt base and gradually decrease
along the crypt–villus axis [74,75]. Concordantly, the
expression of various Wnt ligands (Wnt3, Wnt6 and
Wnt9b) as well as their cognate receptors FZD5/7 is also
highest at the crypt base [42,43,76,77]. Wnts produced by
Paneth cells decorate the membranes of adjacent stem cells
by binding to the highly expressed FZD receptors [78].
Through the regulation of FZD turnover and cell division,
the membrane-bound reservoir of Wnts at the crypt bottom
is gradually diluted, sculpting a gradient of Wnt along the
crypt–villus axis [78]. Accordingly, Wnt target genes display
maximum expression in the crypt base and gradually
decrease moving upward along the crypt domain [40]. Inter-
estingly, Paneth cells themselves also depend on Wnt signals
[42,77,79] and require expression of the Wnt target gene Sox9
for their development and formation [80,81].
5.3. Stem cell-specific Wnt target genes
As described above, ISCs are marked by the Wnt target gene
Lgr5. Transcriptome and proteome analysis of sorted Lrg5-
positive cells unveiled multiple Wnt target genes among
the stem cell-specific gene set [23,82]. Many of these genes
have proven to be essential for stem cell maintenance and
activity, regulating both positive and negative feedback
signalling loops.
Among the ISC-specific Wnt target genes are the trans-
membrane receptor tyrosine kinase genes EphB2 and EphB3
[63]. Their expression is highly enriched on ISCs and Paneth
cells, while transcription of their repulsive ligand, ephrin-B1,
is concomitantly repressed in the crypts. Only upon exiting
the crypt do cells start to express ephrin-B1 as a result of the
decline of Wnt signals. Subsequent repulsive interactions
between EphB-positive and ephrin-B-positive cells results in
segregation of these cells, thereby controlling correct position-
ing of the cells. Indeed, EphB2/3 deficiency in mice results in a
random localization of cells, including Paneth cells, along the
crypt–villus axis. Hence, Wnt signalling controls architectural
integrity of the stem cell zone [63,83–85].TheWnt target gene Ascl2 is expressed in a Wnt-dependent
and highly restricted fashion in ISCs [23–25,62,82,86]. Con-
ditional knockout of Ascl2 in the adult intestinal epithelium
leads to the elimination of CBC stem cells, whereas ectopic
intestinal expression of Ascl2 induces hyperproliferation
of crypts and de novo cryptogenesis in villi [62]. For this
reason, Ascl2 is suggested to be a master regulator of the
crypt stemness programme. Recent research showed that
Ascl2 cooperates with b-catenin/TCF to activate the genes
fundamental to the stem cell state. Ascl2 is activated when
cells reach a specific Wnt/R-Spo signalling threshold and,
as Ascl2 is capable of self-activation, is suggested to translate
the Wnt gradient present in the crypt into a discrete ‘on’ or
‘off’ decision for stemness [25].
Another example of a stem cell-specific Wnt target gene is
Tnfrsf19 or Troy, which is proposed to interact with Lgr5 and
to negatively regulate Wnt/R-Spo signalling. As such, Troy is
proposed to constitute a negative feedback loop to avoid over-
activation of Wnt signalling, thereby preventing subsequent
crypt enlargement and ultimately tumourigenesis [27].
In addition, the stem cell-specific and homologous Wnt
target genes Ring finger 43 (RNF43) and zinc and ring finger
3 (ZNRF3) were shown to act in a negative feedback
manner in the gut [87,88], as discussed below.
In summary, Wnt signalling constitutes the major driving
force behind homeostatic self-renewal of the crypt through
regulation of expression of critical regulatory genes.5.4. Wnt pathway regulation by R-spondin and RNF43/
ZNRF3
R-spondins are a group of small, secreted proteins (R-Spo1–4)
that strongly potentiate Wnt/b-catenin signalling [72,89–93].
R-Spo proteins function as stem cell growth factors and can
promote tissue regeneration [72,94]. Despite their biological
significance there is no consensus on the exact mechanism
by which R-Spo increases Wnt signalling. Various membrane
proteins were proposed to act as R-Spo receptors, including
Wnt receptors FZD and Lrp6 [95,96], Kremen [97], syndecan
4 [98], Lgr4/5 [73,99,100] and membrane E3 ubiquitin ligases
RNF43/ZNRF3 [88,101–107].
To date, Lgrs are largely accepted as the primary receptors
for R-Spo. Lgrs belong to the seven-span transmembrane
receptor family and are known for their large extracellular leu-
cine-rich repeats domain that is involved in ligand binding
[108]. All four members of the R-Spo family can bind to the
leucine-rich domain of Lgr4, Lgr5 and Lgr6 [73,99]. Lgr pro-
teins have been identified as components of the Wnt
receptor complex, and R-Spo binding to Lgr is hypothesized
to stimulate the formation of higher order receptor complexes,
thereby leading to enhanced Wnt signal transduction [73].
A new hypothesis emerged with the discovery of the two
homologous genes RNF43 and ZNRF3 that display strongly
enriched expression in the ISC population [87,88]. These
genes encode for single-span transmembrane E3 ubiquitin
ligases and operate as potent negative feedback regulators
of Wnt signalling to control aberrant expansion of the
crypts. Upon genetic removal of these negative regulators
of Wnt signalling in the intestinal epithelium, mice showed
very rapid tumour formation in the intestine. RNF43 and
ZNRF3 inhibit Wnt signalling by targeting the Wnt receptors




6endocytosis and lysosomal degradation, regulating cellular
sensitivity for incoming Wnt ligands [87,88]. The underlying
mechanism of RNF43/ZNRF3-mediated Wnt receptor target-
ing remains unknown but involves the cytoplasmic effector
Dvl that was found to interact with the cytoplasmic tail of
RNF43 [109]. Another regulatory layer emerged through the
discovery that both RNF43 and ZNRF3 interact with R-Spo
[101,104,106,110–114]. In current models, binding of R-Spo
to Lgr4 recruits the RNF43/ZNRF3 receptors and induces
their membrane clearance [88,105]. R-Spo-mediated removal
of RNF43/ZNRF3 leads to stabilization of Wnt receptors at
the cell surface, strongly enhancing cellular responses to
Wnt (figure 2) [105].
A recent study demonstrates a distinct, non-redundant
cooperation between Wnt and R-Spo ligands in ISC homeo-
stasis and suggests that Wnt ligands act as priming factors
that confer basal proliferative competence to ISCs by main-
taining R-Spo receptor expression, which then drives the
further expansion of stem cells via R-Spo ligands present in
the niche [115].
In summary, the importance of Wnt signalling in collabor-
ation with R-Spo as a major driving force of crypt proliferation
is underscored by its tight regulation through multiple positive
and negative regulatory feedback loops. Both R-Spo and
RNF43/ZNRF3 represent prime examples of Wnt regulators
with key functions in intestinal homeostasis.6. Notch signalling regulates cell fate
decisions and stemness in the crypt
The Notch signalling cascade is a highly conserved cell com-
munication pathway that directs cell fate decisions in
multicellular organisms. The mammalian Notch family com-
prises four single-span transmembrane Notch receptors
(Notch1–4) and five single-span transmembrane Delta/Ser-
rate/Lag2 (DSL) ligands (Jagged (Jag) 1 and 2, Delta-like
(Dll) 1, 3 and 4). Notch signalling is triggered via direct
cell-to-cell contact, through which the membrane-bound
ligands exposed at the juxtaposed cell membrane bind and
activate the Notch receptor. This ligand–receptor engagement
results in the initiation of several proteolytic steps that modu-
late Notch receptor activity. Ultimately, the Notch intracellular
domain (NICD) is released through g-secretase protease
activity (reviewed in [116,117]). Subsequently, NICD translo-
cates to the nucleus to drive gene expression upon binding
of the transcription factor CSL (CBF1, suppressor of hairless,
Lag-1). CSL represses transcription of target genes in unstimu-
lated cells but is converted into a transcriptional activator upon
binding of NICD (figure 2) [118].
In the intestinal crypt, Notch signalling critically regulates
the cell fate decision between absorptive and secretory cell
types. This is illustrated by the use of g-secretase inhibitors,
which block Notch receptor signalling and mediate a massive
conversion of proliferative cells into secretory cells [119,120].
Conversely, enhancement of Notch signalling via intestine-
specific transgenic expression of NICD blocks the commitment
of cells to adopt a secretory lineage fate [121].
The switch between lineages is mainly decided by two
basic helix-loop-helix transcription factors. Notch signalling
induces expression of the transcription factor Hes1 (hairy
and enhancer of split 1) that in turn antagonizes the transcrip-
tion factor Math1 (or Atoh1 (atonal homolog 1)) [122]. Math1is the crucial regulator of the transcriptional programme for
secretory lineage differentiation. Its depletion results in a
complete absence of goblet, Paneth and enteroendocrine
cells in the intestine [123–125], and Math1 overexpression
directs progenitor cells into the secretory lineage [126].
Math1 expression is restricted to the secretory cells of the
intestine, while Hes1 is expressed in most proliferative
crypt cells. Inhibition of Notch signalling rapidly decreases
Hes1 expression and results in upregulatedMath1 expression in
all crypt cells [120]. In line, deletion of Hes1 is associated with
an excess of secretory cells at the expense of enterocytes [122].
Notably, similar phenotypes are observed upon simultaneous
deletion of Notch1 and Notch2 genes and genetic ablation of
CSL [120,127]. In summary, Notch signalling induces Hes1
levels to suppress Math1-dependent differentiation towards
secretory lineages (figure 2).
How does Notch signalling affect ISCs? Lgr5-positive
CBC cells predominantly express Notch1 and Notch2 recep-
tors at the cell surface and Notch1 receptor mRNA was
found enriched in these cells, signifying a regulatory role of
Notch within the CBC stem cell compartment [62,128].
Neighbouring Paneth cells express Notch ligands Dll1 and
Dll4, providing the ligands to activate Notch signalling in
ISCs [10,129]. Notably, lineage-tracing experiments of cells
undergoing active Notch signalling identified long-lived pro-
genitors able to give rise to all the mature epithelial cell types
[129,130]. Inhibition of Notch signalling results in rapid loss
of CBC cells, indicating its requirement for stem cell prolifer-
ation and survival [131]. In particular, the stem cell-specific
marker Olfm4 was shown to be a direct target gene of
Notch signalling [131]. Thus, active Notch signalling is cru-
cial for maintenance and activity of the ISC pool. Recently,
it was shown that Notch signalling also plays a crucial role
in intestinal renewal upon injury by irradiation. Interestingly,
Paneth cells were shown to dedifferentiate and proliferate
and start to line the crypt–villus axis. This newly gained
stem cell-like capacity of Paneth cells is attributed to activated
Notch signalling in the Paneth cells themselves [36].
In summary, Notch signalling regulates different aspects
of intestinal homeostasis, stimulating both stem cell mainten-
ance and cell fate determination of progenitor cells, and can
induce Paneth cells to dedifferentiate upon tissue damage.7. Hedgehog signalling regulates intestinal
mesenchyme
The Hedgehog (Hh) family of secreted ligands consists of
three subgroups; the Desert Hedgehog (Dhh), Indian Hedge-
hog (Ihh), and Sonic Hedgehog (Shh) groups [132]. Binding
of Hh to the twelve-pass transmembrane receptors Patched
1 or 2 (Ptch1/2 or Ptc1–2) activates a signalling cascade
that ultimately drives the activation of the zinc-finger tran-
scription factor glioblastoma (Gli) (Gli1, Gli2 and Gli3),
leading to the expression of Hh specific target genes. In
the absence of Hh ligands, Ptch blocks the activity of the
seven-span transmembrane protein Smoothened (Smo), and
full-length Gli proteins are proteolytically processed to
C-terminally truncated ‘GliR’ (Gli repressor) that actively
repress a subset of Hh target genes. Binding of Hh to Ptch
results in loss of Ptch activity and subsequent activation of
Smo, which transduces the Hh signal to the cytoplasm,




7of Gli proteins into transcriptional activators (GliA) and
thereby induces target gene transcription (figure 2) [132–
136]. Target genes include Ptch1/2, Gli1, Hedgehog-interacting
protein (Hhip) for feedback regulation [132–134,137,138],
and genes that drive proliferation and survival, such as
cyclin D1, myc and Bcl2 [135,139,140].
In the intestine, Ihh is the main hedgehog expressed.
Low levels of Shh may be expressed at the base of the
small intestinal and colonic crypts [141–144]. Ihh is secreted
in a paracrine manner by epithelial cells to act on the sur-
rounding mesenchymal cells, including smooth muscle
precursor and myofibroblast cells [142,145]. In addition, intes-
tinal macrophages and dendritic cells may directly respond to
Hedgehog signalling [145]. Ihh and Shh ligands secreted by
TA cells interact with Ptch receptors localized on mesenchymal
cells to induce BMP production [144,146,147]. BMPs negatively
regulate intestinal epithelial proliferation and restrict the
number of stem cells in the crypt [40,148,149] (see paragraph
below). Furthermore, (Hh downstream factor) Gli1-positive
mesenchymal cells secrete Wnt ligands that are essential for
stem cell renewal in the colon and in the small intestine can
act as a reserve Wnt source [50].
Constitutive activation of Hh signalling, either by sys-
temic deletion of Ptch [144] or by selective overexpression
of Ihh in the intestinal epithelium (Villin-Ihh transgenic
mice) [150], results in an accumulation of mesenchymal
cells. Moreover, experiments in which Hh signalling was con-
ditionally lost in the adult intestine showed that Hh not only
signals for expansion of the mesenchyme but is also required
to maintain smooth muscle and myofibroblast cells [150,151].
Furthermore, analysis of Ihh mutant mice showed that loss of
Ihh signalling ultimately results in the loss of smooth muscle
precursor cells, leading to complete loss of the villus core sup-
port structure [141]. Decreased Hh signalling in the adult
intestine was also shown to enhance Wnt pathway activity,
thereby compromising differentiation and driving crypt
hyperplasia [143].
Thus, in current models, Hh signalling indirectly affects
ISCs via (i) induction of repressive BMP signalling and (ii)
modulation of adjacent stroma for supportive structure.8. Bone morphogenetic protein signalling
regulates crypt formation and terminal
differentiation
BMPs were initially discovered for their ability to induce
bone formation [152] but are now known to play crucial
roles during organ development and tissue homeostasis
[153]. BMPs comprise a class of extracellular signalling mol-
ecules that belong to the transforming growth factor-b
(TGF-b) superfamily of proteins. BMPs signal via the canonical
Smad-dependent pathway and can induce various non-
canonical signalling pathways as well. In the canonical path-
way, BMPs initiate signal transduction by binding to BMP
type I and type II receptors (Bmpr1–2) that form a hetero-
tetrameric complex. BMP receptors are single transmembrane
proteins that carry serine/threonine kinase activity in their
intracellular domains. Upon BMP binding, the constitutively
active Bmpr2 transphosphorylates Bmpr1. Subsequently,
Bmpr1 phosphorylates the receptor-bound R-Smads1/5/8
(receptor-regulated Smads). Phosphorylated Smad1/5/8then associate with the core mediator Smad4, and the resulting
Smad complex translocates to the nucleus to associate with
coactivators or corepressors and regulate gene expression pat-
terns (figure 2) [153,154]. BMP target genes include Msx
homeobox genes and the proto-oncogene JunB [155,156]. Path-
way activity is regulated by extracellular antagonists, such as
Noggin, follistatin or gremlin, that sequester BMP ligands,
thereby blocking interaction with BMP receptors [157].
In the intestine, the BMP pathway acts as a negative
regulator of crypt formation and drives the terminal differ-
entiation of mature intestinal cells [148,158,159]. BMP-2
and -4 ligands are expressed by both mesenchyme and epithelial
villus cells and mainly act on the epithelial compartments
that contain differentiated cells expressing BMP receptors
[148,160]. Mesenchyme-to-epithelium BMP signalling pro-
motes differentiation of progenitor cells while restraining
cell proliferation [149]. BMP signalling within the crypt
base stem cell niche is carefully regulated by BMP antagon-
ists, such as gremlin1/2, chordin, Noggin and ANGPTL2,
expressed by the mesenchyme surrounding the crypt
[40,161,162]. Inhibition of BMP signalling in the mouse
villus using transgenic expression of the BMP inhibitor
Noggin, results in ectopic crypt formation [148]. Similarly,
conditional deletion of Bmp receptor 1A results in hyper-
proliferative crypts [149]. BMP represses Wnt signalling
and is expressed in an opposing gradient along the
crypt–villus axis, with highest BMP signalling in the cells
at the luminal surface (figure 1) [149].9. EGF signalling is required for intestinal
stem cell proliferation
EGF is an extracellular ligand that stimulates cell growth,
proliferation, and differentiation by binding to its cognate
receptor the epidermal growth factor receptor (EGFR). EGFR
is also known as ErbB1/HER1, and is a member of the
ErbB family of receptor tyrosine kinases. Upon activation by
EGF binding, EGFR undergoes a transition from an inactive
monomeric form to an active homodimer. EGFR dimerization
stimulates its intrinsic intracellular protein-tyrosine kinase
activity. As a result, several tyrosine residues in the C-terminal
domain of EGFR are autophosphorylated, which drives
downstream pathway activation. Downstream signalling
effectors associate with phosphorylated tyrosines in the EGF
receptor via their SH2 domains and initiate major cellular
pro-survival and proliferation signalling cascades, including
the mitogen-activated protein kinase (MAPK), phosphatidyl-
inositol 3-kinase (PI3K)/Akt, c-Jun N-terminal kinases (JNK),
Jak/STAT and phospholipase C (PLC) pathways (figure 2)
[163,164]. Of note, the small GTPase KRAS (Kirsten rat sarcoma
viral oncogene homolog) acts as a crucial central relay in a
number of these signalling cascades and is commonly mutated
in colorectal cancers [165,166].
EGF signalling is required for proliferation and mainten-
ance of ISCs and is produced in the niche by the surrounding
Paneth cells and subepithelial mesenchyme [10,42]. In turn,
EGFR is highly expressed in ISCs and in TA cells [167].
Indeed, luminally applied EGF strongly induces proliferation
of the small intestinal epithelium in rats [168,169]. By con-
trast, blockade of EGF signalling in organoids converts
actively dividing ISCs into quiescent Lgr5þ reserve stem




8[170]. Evidently, tight control is necessary to balance EGF-
induced proliferation of ISCs. To this end, ISCs express
high levels of the EGFR/ErbB inhibitor leucine-rich repeats
and immunoglobulin-like domains protein 1 (Lrig1) trans-
membrane proteins. Lrig1 is an inducible negative feedback
regulator of the ErbB receptor family that mediates the ubiqui-
tination and subsequent degradation of canonical EGFRs
[32,33,171]. Accordingly, genetic ablation of Lrig1 in mice
results in enhanced EGFR/ErbB expression leading to an
increase in ISC numbers and significant expansion of
crypts [32,33]. This activity of EGFR signalling in intestinal
maintenance is highly conserved, as shown by studies using
Drosophila [172,173].
In summary, controlled expression of Lrig1 forms a nega-
tive feedback loop that allows stem cells to fine-tune their
cellular response to EGF ligand-mediated signalling and
ensures proper crypt size and tissue homeostasis.
Of note, a recent study demonstrated redundancy
between EGF and hepatocyte growth factor (HGF) in the
intestine. HGF regulates intestinal homeostasis and regener-
ation by engaging its receptor MET, and interestingly HGF/
MET signalling can fully substitute EGFR signals in intestinal
organoid cultures [174].10. Eph–ephrin signalling directs
appropriate cell positioning along the
crypt–villus axis
Eph–ephrin signalling occurs via direct cell–cell contact and
is involved in a wide spectrum of biological processes,
including the regulation of cell positioning. Ephrin ligands
are divided into two subclasses based on their structure
and mode of linkage to the cell membrane (ephrin-A and
ephrin-B). Ephrin-A proteins are anchored to the membrane
by a glycosylphosphatidylinositol (GPI) linkage and lack a
cytoplasmic domain, while ephrin-B proteins pass the mem-
brane by their single transmembrane domain and contain a
short cytoplasmic part. Eph receptors constitute the largest
family of tyrosine kinase receptors and can be divided into
the subclasses EphA and EphB, based on sequence similarity
and binding affinities for either ephrin-A or -B [175,176].
A unique feature of Eph–ephrin signalling is that both
receptor and ligand are competent to transduce signalling
upon interaction. This concept of bidirectional signalling
has emerged as an important mechanism by which Ephs
and ephrins control cell–cell communication. Eph- and
ephrin-mediated signalling are generally referred to as for-
ward and reverse signalling, respectively [176]. Essentially,
Eph signalling controls cell morphology, adhesion and
migration by modifying the organization of the actin cyto-
skeleton and influencing the activities of integrins and
intercellular adhesion molecules [85,176]. Upon binding of
an ephrin ligand to the extracellular domain of an Eph recep-
tor, intracellular tyrosine and serine residues of the receptor
are auto-phosphorylated, allowing the cytoplasmic tyrosine
kinase to subsequently activate and modulate downstream
signalling cascades, such as MAPK, Ras and ERK signalling
(figure 2) [85,177].
Although Eph–ephrins were initially studied mainly in a
developmental context, their physiological functions in adult
tissues are rapidly coming to light. In the intestine, highlevels of Wnt signalling induce expression of EphB2 and
EphB3 in the lower parts of the crypts with simultaneous tran-
scriptional repression of their repulsive ephrin-B1 ligand [63].
Of note, Notch signalling activates the expression of ephrin-B1
in differentiated intestinal cells [178]. ISCs display high levels
of EphB2 expression, while Paneth cells are EphB2 negative
but express EphB3 [63,179]. The decline in Wnt cues along
the crypt–villus axis results in de-repression of the repulsive
ephrin-B1 ligand. At the same time, EphB2 expression pro-
gressively declines in TA cells as they migrate upwards. The
gradient of repulsive EphB2/3–ephrin-B1 interaction coordi-
nates appropriate cell positioning along the crypt–villus axis
with differentiated cells moving upwards towards the villus
tip [63,83,180,181]. Differentiated Paneth cells that highly
express EphB3 escape this upward flow and move towards
the crypt bottom. Indeed, in EphB3 null mice, Paneth cells
are not restricted to crypts but spread randomly along the
villi in the small intestine [63].11. Interconnectivity of signalling pathways
governs crypt–villus homeostasis
Each of the above-described signalling pathways controls
intestinal homeostasis, through either a direct or indirect
modulation of ISC behaviour. ISCs interpret these signals
derived from the niche to ensure the balance between cell
loss and cell replenishment, thereby safeguarding tissue
maintenance. The interconnectivity of the signalling path-
ways further secures an appropriate strength and timing of
signals within the stem cell niche. The Wnt pathway is the
main force behind intestinal epithelium homeostasis and
requires tight regulation to prevent hyperproliferation of
ISCs. The expression of stem cell regulatory Wnt ligands dis-
plays a diminishing slope along the crypt–villus axis. At the
þ4 position, a local production of Wnt antagonists is
observed, including Wnt binding secreted Frizzled-related
proteins, likely to keep the reserve stem cells at that position
in the quiescent state [76]. In the crypt, the Wnt pathway
synergizes with Notch signalling to sustain undifferentiated
and proliferative stem and progenitor cells in the crypt.
Additionally, both pathways are essential for specific lin-
eage commitment of progenitor cells along the absorptive
(Notch) and secretory (Wnt) cellular differentiated states.
Interestingly, inhibition of Notch signalling, using Notch
blocking antibodies, caused conversion of Lgr5-expressing
ISCs to secretory cells, leading to stem cell depletion. This
coincided with Wnt pathway upregulation and increased
secretory cell differentiation. Repression of canonical Wnt
signalling rescued this phenotype, suggesting opposing
and interconnected activities of Notch and Wnt signalling
to guide gut homeostasis [182].
Furthermore, Wnt signalling induces high crypt-specific
expression of EphB2 and EphB3, while the decreasing Wnt
gradient along the crypt–villus axis generates an opposing
gradient of the repulsive ephrin-B ligand, securing spatial
segregation and accurate positioning of distinct cellular com-
partments within the crypt. In the upper part of the crypt and
within the villus, the output of Wnt signalling is modulated
by cooperative activity of the paracrine Hedgehog and BMP
signalling cascades. As the progenitor cells move upwards
from the crypt base, the Hedgehog-induced, mesenchyme-
to-epithelium BMP signalling promotes differentiation while
Wnt























Figure 3. Interconnectivity of signalling pathways governs crypt–villus homeostasis. Intestinal homeostasis and cell fate determination are maintained by inter-
connectivity of key signalling pathways between epithelial and mesenchymal cells. Wnt ligands (centre) secreted from the Paneth cells and intestinal subepithelial
myofibrobasts act predominantly at the base of the crypt to maintain stem cell function and TA cell proliferation. High levels of Wnt signalling induce the expression
of EphB2 (ISCs) and EphB3 (Paneth cells), and concurrently repress transcription of the repulsive ligand ephrin-B1. The decline in Wnt signals along the axis results in
increased ephrin-B1 levels and proper positioning of the cells. EGF signalling (left) is required for proliferation and maintenance of ISCs and is produced in the ISC
niche by the surrounding Paneth cells and subepithelial mesenchyme. Notch signalling regulates cell fate through cell-to-cell contact in the crypt (here for simplicity
only visualized on the top left). Notch signalling controls the binary cell fate decision between the secretory and absorptive lineages. Hedgehog (Hh), expressed by
epithelial cells in the upper part of the crypt, acts upon and maintains the myofibroblasts. This has a secondary effect on the epithelium through promotion of BMP
ligand expression. BMP ligands are predominantly produced by the mesenchymal cells and partly by epithelial villus cells. Mesenchyme-to-epithelium BMP signal-
ling promotes differentiation of progenitor cells while restraining cell proliferation. BMP signalling within the crypt stem cell niche is therefore carefully regulated by





9restraining cell proliferation. Importantly, at the crypt
base, the pro-differentiation activity of the BMP pathway
is counteracted by locally secreted mesenchyme-derived
BMP antagonists. Also, Paneth cell-derived EGF-induced
mitotic signalling at the crypt base is balanced by expression
of EGFR inhibitor Lrig1.
Collectively, an interconnected network of developmental
signalling pathways governs intestinal homeostasis by balan-
cing the processes of cell proliferation and differentiation
(figure 3).12. Sequential mutation of ‘niche-like’
signalling pathways drives intestinal
carcinogenesis
Disruption of the delicate balance between proliferation and
differentiation governed by key signalling pathways in the
crypt can lead to hyperproliferation and ultimately tumour
growth. Indeed, cancer cells inappropriately turn on a gene
programme for self-renewal and survival by acquiring
mutations in key components of signalling pathways that are
normally provided by the external cues from the niche [183].
The majority of colorectal tumours evolve from benign to
malignant lesions by acquiring a series of mutations over
time: the adenoma–carcinoma sequence [184,185]. Formation
of benign adenomas is initiated by activation of the Wnt sig-
nalling pathway, most commonly through inactivating
mutations in APC [186]. Subsequent activating mutations in
the EGFR pathway (KRAS, PIK3CA), and inactivatingmutations in the TGF-b/BMP pathway (SMAD4) as well
as in p53 (TP53) promote progression to an invasive and
metastatic phenotype [184,185,187]. Mutations in these
genes are presumed to drive colorectal carcinogenesis as
they provide selective growth advantages to the mutated
cells and are therefore called ‘driver’ mutations. Each
human colorectal carcinoma (CRC) is regarded to harbour
three to six recurrent driver mutations [187]. Recently,
two elegant studies showed, using CRISPR–Cas9-engin-
eered organoid cultures, that a combination of at least
four of such driver mutations liberates the ISC from the
need of niche factors, rendering gut organoid growth
entirely self-sufficient [188,189]. Importantly, such mutant
organoids form tumours after transplantation in mice
[188,189]. Hence, the introduction of driver mutations in
organoids fully copies the CRC phenotype and provides
final proof that the sequential disruption of key signalling
pathways governs the adenoma–carcinoma sequence.
Activation of the Wnt and the EGFR signalling pathways
represent key steps in the initiation and early progression of
CRC, by favouring stemness and proliferative characteristics.
Subsequent blockade of BMP/TGFb signalling suppresses
differentiation and further tilts the balance towards prolifer-
ation of the cancer cells. Ultimately, inactivation of p53
results in loss of DNA damage control and, more impor-
tantly, allows CRC cells to escape apoptosis. Together, this
establishes an optimal combination of events for cancer cell
survival and carcinogenesis.
Interestingly, the combined inactivation of both APC and
p53 appears already sufficient to induce extensive aneu-




10number of driver mutations in CRC is variable, with a frac-
tion of CRCs carrying only a single pathway alteration
[190]. In these cases, acquired microsatellite and/or chromo-
somal instability and epigenetic changes might alter driver
pathway signalling instead.
Clearly, the sequential accumulation of driver mutations
drives tumour progression towards CRC, but are the initial
genetic alterations also required to maintain CRC cells at
later stages of tumour progression? This question was
recently addressed by Dow et al. [191] using a conditional
short hairpin RNA approach to control APC levels in a
subset of ISCs in the mouse. The strong reduction of
APC levels initiated tumour formation along the intestine,
including the colon. Upon restoration of APC expression,
tumours regressed and CRC cells underwent differen-
tiation toward normal intestinal cell types, thereby
reinstating crypt–villus homeostasis. Strikingly, invasive
tumours harbouring additional KRAS and TP53 mutations
were also reverted to normal functioning cells after rein-
troduction of APC [191]. This illustrates that loss of APC
is not only essential for CRC onset but remains critical
for CRC maintenance even in the presence of sequential
driver mutations.13. Concluding remarks
In this review, we summarized our understanding of the
unique properties and regulated activity of ISCs. A plethora
of genetic studies have provided instrumental insights into
the signalling networks that govern intestinal homeostasis.
Crypt cells display substantial plasticity that is influenced
by signals from the stem cell niche. Perturbations within
these signalling pathways, most prominently the Wnt cas-
cade, can induce tumourigenesis. A better understanding of
the relationships and interconnectivity between homeostatic
signalling and distinct aspects of tumour initiation and pro-
gression will be critical in the discovery of potential targets
and development of strategies for therapeutic intervention.
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